LEADER 04197nam  2201201z- 450 
001 9910580204803321
005 20220706
035   $a(CKB)5690000000012042
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/87408
035   $a(oapen)doab87408
035   $a(EXLCZ)995690000000012042
100   $a20202207d2022      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aRecent Advances in Antibody Therapeutics
210   $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022
215   $a1 online resource (238 p.)
311 08$a3-0365-4353-8 
311 08$a3-0365-4354-6 
330   $aSince first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, "Recent Advances in Antibody Therapeutics", presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies
606   $aChemistry$2bicssc
606   $aResearch & information: general$2bicssc
610   $aaffinity maturation
610   $aagonist antibody
610   $aanti-angiogenesis
610   $aanti-cancer antibody
610   $aantibodies
610   $aantibody
610   $aantibody engineering
610   $aantibody therapeutics
610   $aantibody therapy
610   $aantibody-drug conjugates
610   $aantigen
610   $aasthma
610   $aatherosclerosis
610   $abinding assays
610   $abioassays
610   $abiochemical and physicochemical properties
610   $abiomarker
610   $abiophysical properties
610   $abispecific antibodies
610   $abladder cancer
610   $ablood-brain barrier
610   $abrain shuttle
610   $aC2_2E12
610   $acell fate
610   $acombinatorial antibody library
610   $acomputational methods
610   $acost-effectiveness
610   $acytomegalovirus
610   $adelta-like ligand
610   $adisposition
610   $aenfortumab vedotin
610   $aerdafitinib
610   $aFc binding
610   $aG protein-coupled receptor
610   $aHPV cancer therapy
610   $aHPV oncoproteins
610   $aHPV-associated cancer
610   $aHuman papillomaviruses
610   $aimmune checkpoint inhibitors
610   $ainflammation
610   $ainterleukin 33
610   $aintracellular antibodies
610   $airinotecan
610   $amechanisms of action
610   $amembrane protein
610   $amolecular Trojan horse
610   $amonoclonal antibody
610   $an/a
610   $ananobody
610   $apaclitaxel
610   $apeptide/major histocompatibility complex class I complex
610   $aphage display
610   $apharmacokinetics
610   $apotency assays
610   $areceptor-binding domain
610   $areceptor-mediated transcytosis
610   $arecombinant antibodies
610   $arefractory asthma
610   $aresearch cell bank
610   $asacituzumab govitecan
610   $aSARS-CoV-2
610   $ascFv
610   $asingle-chain antibody fragment
610   $aspike protein
610   $aST2 receptor
610   $aT-cell-receptor-like antibody
610   $atherapeutic antibody
610   $atransferrin
610   $aVEGF
610   $ayeast surface display
615  7$aChemistry
615  7$aResearch & information: general
700   $aHeo$b Yong-Seok$4edt$01332302
702   $aHeo$b Yong-Seok$4oth
906   $aBOOK
912   $a9910580204803321
996   $aRecent Advances in Antibody Therapeutics$93040802
997   $aUNINA